Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa
Collectively, the broad activity of topical ruxolitinib on inflammatory signalling processes resulted in promising efficacy, even with heterogeneity in baseline inflammation, in this pilot cohort. Importantly, topical treatment not only resolved epidermal inflammation, but also cleared deeper inflammatory infiltrate. The observed efficacy provides rationale to further investigate topical JAKi and other novel topical treatments in HS.
Authors
- Joslyn S. Kirby (ORCID: https://orcid.org/0000-0002-6741-3796)
- Mackenzie L. Sennett (ORCID: https://orcid.org/0000-0003-4964-3835)
- Robert P. Feehan (ORCID: https://orcid.org/0000-0001-5368-1872)
- Amanda M. Nelson (ORCID: https://orcid.org/0000-0001-6375-8706)
- Matthew F. Helm (ORCID: https://orcid.org/0000-0001-7469-8569)
- Amy L. Longenecker (ORCID: https://orcid.org/0000-0002-3804-2789)
- Stephanie L Schell (ORCID: https://orcid.org/0000-0001-5963-4938)
- Elizabeth C Meiszberg
- Thomas Wallace (ORCID: https://orcid.org/0009-0003-2116-3204)
Institutions
- Pennsylvania State University (US)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1093/bjd/ljae495
- Citations
- 10
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.35